ArticleBMC cancer2026
Radiomics of T2-weighted MRI for pretreatment prediction of prognosis and temozolomide chemosensitivity in glioma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundWe aimed to construct and validate a radiomics prediction model based on preoperative T2-weighted MRI for prognosis and chemosensitivity prediction in patients with glioma.
methodsA total of 576 glioma patients were enrolled in this study. The training and validation group included 324 patients and 127 patients respectively with preoperative MRI image data, tumor transcriptome sequencing data and clinical information. The prospective validation group consisted of 125 patients with preoperative MRI image data and clinical information. The radiomics prediction model was constructed based on the prognostic relevant radiomic features of glioma patients in the training group. The radiomics prediction model was validated inpatients of retrospective and prospective validation groups. Functional annotation of radiomic features was performed by pearson correlation analysis of biological process scores and radiomic features values of patients in the training group and validated by transcriptome sequencing, single cell sequencing, reactive oxygen species detection and endoplasmic reticulum stress detection of tumors of patients in retrospective and prospective validation groups.
resultsThe radiomics prediction model, which consisted of 17 radiomic features, showed highly predictive stability in overall survival and progression-free survival prediction. Compared with patients who underwent postoperative radiotherapy alone, only patients in the high-risk group benefited from postoperative chemoradiotherapy. The prognostic relevant radiomic features were closely related to immune response, reactive oxygen species metabolism and endoplasmic reticulum stress of glioma cells in silico and in vitro.
conclusionsThe radiomics prediction model serves as a non-invasive tool to predict prognosis and temozolomide chemosensitivity of glioma patients based on preoperative T2-weighted MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.